Monitor for any conversion of this 13G to a 13D (activist filing) or further stake increases. The cluster of institutional filings post-offering suggests a stable shareholder base, but the 9.9% position is near the threshold that could trigger activist considerations.
YARW drugs
YARW drug pipeline →Price Chart
How similar events traded
Executive Summary
RTW Fund Group GP, LLC filed an amended Schedule 13G disclosing a 9.9% beneficial ownership stake in Yarrow Bioscience as of September 30, 2026, representing 1,145,149 shares (including warrants). This is an increase from a prior filing (0.46% by Nantahala Capital) and adds to a series of recent 13G filings by other institutions (Bellevue Group at 10.6%, Spruce Street at 6.4%) following Yarrow's September 2026 equity offering. The passive certification and hedge fund identity suggest a routine investment, not an activist precursor.
Key Financial Metrics
Key Facts
- RTW Fund Group GP, LLC disclosed a 9.9% beneficial ownership stake in Yarrow Bioscience as of September 30, 2026.
- The stake includes 1,145,149 shares of common stock, with warrants exercisable up to a 9.99% ownership cap.
- This is an amendment to a prior Schedule 13G filed on July 30, 2026, reflecting an increased position.
- The filing is passive (Rule 13d-1(b)) with no activist intent certified.
- Other recent 13G filers include Bellevue Group (10.6%) and Spruce Street Capital (6.4%).
Financial Impact
9.9% stake valued at approximately $18.1M based on $183M market cap.
Risk Factors
- Potential future conversion to activist filing (13D) if intent changes.
- Dilution risk from outstanding warrants and recent equity offering.
- Pre-revenue clinical-stage biotech with no approved products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0002147397-26-000003 |
| Document: 0002147397-26-000003-index.html | 0002147397-26-000003 |
| Document: 0002147397-26-000003.txt | 0002147397-26-000003 |
Track record
13 reports on YARW
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 17, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $14.20 Now $14.27 +0.49% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
- Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $15.44 Now $14.27 −7.58% settles Dec 15
- Nov 16, 20261d ago SC 13G Neutral 3/10 Entry $18.20 Now $14.27 −21.59% settles Dec 15
- Nov 16, 20261d ago SC 13G/A Neutral 3/10 Viewing Entry $18.03 Now $14.27 −20.85% settles Dec 15
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $17.35 Now $14.27 −17.75% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $18.03 Now $14.27 −20.85% settles Dec 15
- Nov 12, 20265d ago 8-K Neutral 4/10 Entry $19.63 Now $14.27 −27.31% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers